Ecovyst Inc. (ECVT) Prices 8M Share Secondary Offering at $9.50/sh

Ecovyst Inc. (NYSE: ECVT) today announced the pricing of the previously announced underwritten public offering by certain of its stockholders (the “Selling Stockholders”) of 8,000,000 shares of its common stock at a price to the public of $9.50 per share. The offering is expected to close on November 23, 2021, subject to customary closing conditions. The Selling Stockholders have granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares at the public offering price less underwriting discounts and commissions.

The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company.

Citigroup, Deutsche Bank Securities and Credit Suisse are serving as the joint lead book-running managers of the offering. BMO Capital Markets, Morgan Stanley, Jefferies and KeyBanc Capital Markets are also serving as book-running managers of the offering. C.L. King & Associates are serving as a co-manager of the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the Securities and Exchange Commission (“SEC”) on April 26, 2021 and became effective upon filing. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146) or Deutsche Bank Securities Inc., Attention: Prospectus Department, 1 Columbus Circle, New York NY, 10019, by telephone at 1-800-503-4611 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Aveanna Healthcare prices secondary offering at $11.75 per share
• Kairos Pharma announces 1-for-7 reverse stock split